Multiple STIs Could Be Detected with A Single Rapid Test
|
By LabMedica International staff writers Posted on 26 Apr 2016 |

Image: A disposable cartridge for testing for a sexually transmitted disease (Photo courtesy of Atlas Genetics).
One test that could detect four of the most common sexually transmitted infections (STIs) in 30 minutes and allow them to be rapidly treated is under development. A GBP150,000 grant has been awarded to develop the test that will detect STIs, including chlamydia and gonorrhea.
Testing kits have been sent out by the UK National Chlamydia Screening Program aimed at those aged under 25 who did not have symptoms but wished to know they are clear of the infection. Their samples were then sent away for testing and those who tested positive for Chlamydia were offered the opportunity to trial the new technology.
Chlamydia is the UK’s most common STI with about 100,000 cases diagnosed each year and people under 25 years old are most at risk. If untreated, it can have serious long-term health consequences, including infertility in women. In some areas, one in five people never get treatment for their infection and others wait a long time before coming back to a clinic.
The test is being developed by scientists at St George’s, University of London (UK) and Atlas Genetics (Trowbridge, UK). The STI multiplex combines tests for four major nucleic acid targets, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, without the need for microscopy. The test is run on the Atlas Genetics’ io system which is a fully automated solution, requiring minimal hands-on time. Following the addition of an unprocessed patient specimen on to the io Cartridge, the Cartridge is then inserted in to the io Reader.
Tariq Sadiq MD, chief investigator at St. George’s, leads the eSTI2 Consortium which has developed a new smartphone app which allows patients to access an electronic clinic, the eSexual Health Clinic, to get rapid online treatment for chlamydia infection once they were diagnosed. Using a secure National Health System (NHS) log in, the app included an online medical consultation, leading to an electronic prescription for antibiotics, which patients could collect at a high street pharmacy. The app also enabled the patients’ sexual partners to get treatment quickly and easily in the same way. A clinical helpline is available for patients who need advice or support.
Eventually the eSexual Health Clinic will link to a hand held diagnostic device for STIs is also being developed by the scientists. This will mean that a urine or swab sample from patients would not have to be sent away for analysis, but can be analyzed at home so patients would receive their results within half an hour and then get their care online without ever needing to see a doctor face to face or attend a clinic.
Related Links:
St George’s, University of London
Atlas Genetics
Testing kits have been sent out by the UK National Chlamydia Screening Program aimed at those aged under 25 who did not have symptoms but wished to know they are clear of the infection. Their samples were then sent away for testing and those who tested positive for Chlamydia were offered the opportunity to trial the new technology.
Chlamydia is the UK’s most common STI with about 100,000 cases diagnosed each year and people under 25 years old are most at risk. If untreated, it can have serious long-term health consequences, including infertility in women. In some areas, one in five people never get treatment for their infection and others wait a long time before coming back to a clinic.
The test is being developed by scientists at St George’s, University of London (UK) and Atlas Genetics (Trowbridge, UK). The STI multiplex combines tests for four major nucleic acid targets, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, without the need for microscopy. The test is run on the Atlas Genetics’ io system which is a fully automated solution, requiring minimal hands-on time. Following the addition of an unprocessed patient specimen on to the io Cartridge, the Cartridge is then inserted in to the io Reader.
Tariq Sadiq MD, chief investigator at St. George’s, leads the eSTI2 Consortium which has developed a new smartphone app which allows patients to access an electronic clinic, the eSexual Health Clinic, to get rapid online treatment for chlamydia infection once they were diagnosed. Using a secure National Health System (NHS) log in, the app included an online medical consultation, leading to an electronic prescription for antibiotics, which patients could collect at a high street pharmacy. The app also enabled the patients’ sexual partners to get treatment quickly and easily in the same way. A clinical helpline is available for patients who need advice or support.
Eventually the eSexual Health Clinic will link to a hand held diagnostic device for STIs is also being developed by the scientists. This will mean that a urine or swab sample from patients would not have to be sent away for analysis, but can be analyzed at home so patients would receive their results within half an hour and then get their care online without ever needing to see a doctor face to face or attend a clinic.
Related Links:
St George’s, University of London
Atlas Genetics
Latest Technology News
- AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
- AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
- AI Model Achieves Breakthrough Accuracy in Ovarian Cancer Detection
- Portable Biosensor Diagnoses Psychiatric Disorders Using Saliva Samples
- Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement

- Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
- Viral Biosensor Test Simultaneously Detects Hepatitis and HIV
- Acoustofluidic Device to Transform Point-Of-Care sEV-Based Diagnostics
- AI Algorithm Assesses Progressive Decline in Kidney Function
- Taste-Based Influenza Test Could Replace Nasal Swabs with Chewing Gum
- 3D Micro-Printed Sensors to Advance On-Chip Biosensing for Early Disease Detection
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Microfluidic Device Predicts Pancreatic Cancer Recurrence After Surgery
Pancreatic ductal adenocarcinoma is one of the deadliest cancers, difficult to detect early, and prone to recurring in nearly 70% of patients after treatment. Its location deep in the abdomen and its aggressive... Read more
New Molecular Test Simultaneously Detects Three Major Fungal Infections
Serious fungal infections associated with soil exposure remain difficult to diagnose promptly, especially in regions where Histoplasma, Blastomyces, and Coccidioides are endemic. Many patients present... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read more
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read morePathology
view channel
AI Tool to Transform Skin Cancer Detection with Near-Perfect Accuracy
Melanoma continues to be one of the most difficult skin cancers to diagnose because it often resembles harmless moles or benign lesions. Traditional AI tools depend heavily on dermoscopic images alone,... Read more
Unique Immune Signatures Distinguish Rare Autoimmune Condition from Multiple Sclerosis
Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) is a rare autoimmune disorder in which the immune system attacks the myelin sheath in the central nervous system. Although symptoms... Read moreTechnology
view channel
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more




 assay.jpg)



